Sign Up | Log In | What is SocialPicks?

Good Investment Ideas By People You Trust

SocialPicks is a community where stock investors exchange ideas and track performance of financial bloggers.

Are you a stock guru?

Share picks & earn reputation

Mike Havrilla twitter.com/mikehavrilla

Start Tracking Mike Havrilla - Add to Friends - Send Message

Community Rank: Principal (7000 pts) | Member since 07/15/2008

Picks Performance:

Outperforms

73%

of community

What's this?

All-time Return +1.04% (in 1 year)	Risk (SD) Conservative 0.00%	Sharpe Ratio -2.09
Followers 68	Winning Picks 786 of 1807	Total Views 945599

Overview

Stocks

Stats

Community

Widget

Last Activity: Added DNDN to bullish list on 11/28/09

Current Stock List:

Symbol	SP Sentiment	Return	Since
DNDN		-0.22%	11/28/09
UNIFF	N/A	n/a	11/28/09
CLDA	N/A	+3.76%	11/26/09
PBIO	N/A	-9.25%	11/24/09
PUMD	N/A	n/a	11/23/09
SCLN	N/A	-12.36%	11/23/09
TSPT	N/A	-37.43%	11/23/09
ABIO		+33.33%	11/23/09
NVO		+2.28%	11/22/09
BIO		-2.67%	11/19/09

All-time Sectors of Interest

... View All >

Opinion & Analysis

Cancer Vaccines: Investing Opportunities beyond Den.. about DNDN 11/28/09
Despite the setbacks and pitfalls experienced by early-stage pioneers in the cancer immunotherapy / therapeutic cancer vaccine space such as Cell Genesys, Favrille, and Genitop...

Unilife (UNIFF.PK) CEO Video Interview on CNBC about UNIFF 11/28/09
Unilife Medical Solutions (ASX: UNI.AX) (OTC: UNIFF.PK) is an emerging medical device manufacturer with business segments that include pre-filled syringes for pharmaceutical companies to deli...

BioMed Research Reports: Clinical Data (NASDAQ: CLD.. about CLDA 11/26/09
The BioMedReports.com research download section has been updated to include PDFs for two recent research reports written by Griffin Securities for Clinical Data (NASDAQ: CLDA) ...

Under the Radar Healthcare Stocks: Protox, Pressure.. about PBIO 11/24/09
Below are three under the radar stocks from the healthcare sector that I have been following for the past 3-6 months which have upcoming catalysts in the form of expected strategic deals, clinical tri...

BioMed News Bytes: Transcept, SciClone, ProUroCare,.. about PUMD 11/23/09
On 11/23/09, Transcept Pharma (NASDAQ: TSPT) announced that it is scheduled to meet with the FDA on 1/20/10 to discuss the Complete Response Letter (CRL) regarding the New Drug Application (NDA) for I...

... View All >

Blog Posts

MM ONTY Oncothyreon (ONTY) Research Note 03/18/09 — Visit the BioMedReports.com research section to view or download the PDF for Cougar Biotechnology (CGRB) along with other free PDF reports and corporate investor presentations:http://biomedreports.com/research.htmlOncothyreon (ONTY): Price: $1.21; Market Cap (MM): $23.6Market Outperform; Target Price...

Read 1 comment

MM CGRB Cougar Biotech Research Note 03/17/09 — Visit the BioMedReports.com research section to view or download the PDF for Cougar Biotechnology (CGRB) along with other free PDF reports and corporate investor presentations:http://biomedreports.com/research.htmlCGRB: Price: $28.46; Market Cap (MM): $590.1Market Outperform; Target Price: $36.00Simo...

Read 0 comments

DRRX UTHR Updated Clinical Trial and FDA Calendars 03/17/09 — Below is a summary of updates to the www.BioMedReports.com database of 243 entries included in the FDA and Clinical Trial Calendars.http://biomedreports.com/fda-calendar.html The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FD...

Read 0 comments

MM SNTA Synta Pharma Proceeds with Clinical Trial 03/17/09 — Visit the BioMedReports.com research section to view or download the PDF for Synta Pharma (SNTA) along with other free PDF reports and presentations:http://biomedreports.com/research.htmlSynta Pharma: Price: $1.94; Market Cap (MM): $65.8Market Perform; Simos Simeonidis, Ph.D. - Senior Biotech Analyst...

Read 0 comments

MM PARD Poniard Pharma Awaits Key Cancer Drug Data 03/17/09 — Visit the BioMedReports.com research section to view or download the six page PDF for Poniard Pharma (PARD) along with other free PDF reports and presentations:http://biomedreports.com/research.htmlPARD: Price: $1.87; Market Cap (MM): $64.9Market Outperform; Target Price: $10.00Simos Simeonidis, Ph.D...

Read 0 comments

... View All >

Discussions

Mike Havrilla hasn't participated in any discussions yet.

People Following Mike Havrilla ...

mbmalone

Analyst

N/A

Chris Bramhall

Sr. Analyst

52%

Jeremy McDonald

Associate

76%

... View All >

Mike Havrilla is Following ...

Jeremy McDonald

Associate

76%

Locationh

Sr. Associate

61%

Mathieu Godbout Paquet

Principal

73%

... View All >

Friends of Mike Havrilla ...

charmed

Analyst

N/A

sivoodoo

Analyst

N/A

Greg

Associate

73%

... View All >

Similarity to Me ?

Compare Your Portfolio With Mike Havrilla: Enter stocks you like & track your portfolio:

Symbols, separated by space (e.g. AAPL GOOG MSFT)

More about Mike Havrilla

Investment Style:
Moderate [?]

Avg exp holding time:
87.74 days

Age: 30's	Occupation: Online Media Entrepreneur
Location: USA

Website:
twitter.com/mikehavrilla

About Me:

Mike Havrilla is an index developer, pharmacist, writer, and Co-Founder of BioMedReports.com with ex ... more

Similar Portfolios

Marian Filo (supratrade) 62% 55%

Art (unicomtrade.com) N/A 32%

Statistician (optimist) N/A 32%

Steven Halpern (trackstevenhalpern_bloggingstocks) 56% 21%

Zacks.com (zacks.com) 28% 21%

IN THE PRESS

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.